

Immune Responses Against *Mycobacterium tuberculosis* and the Vaccine Strategies

Toshi Nagata¹ and Yukio Koide²

¹Department of Health Science, Hamamatsu University School of Medicine, Hamamatsu

²Department of Infectious Diseases, Hamamatsu University School of Medicine,
Hamamatsu
Japan

1. Introduction

Tuberculosis (TB) is an infectious disease caused by *Mycobacterium tuberculosis* (Mtb). Robert Koch identified Mtb as a causative agent of TB at 1882 (Sakula, 1983). Since then, TB has been one of the most important infectious diseases for human being. According to the WHO report regarding the global burden of TB in 2009, there were 9.4 million incident cases of TB with approximately one third of the world total population being infected (World Health Organization, 2010). Especially, coinfection of Mtb and HIV is a serious issue in sub-Saharan Africa area. Distribution of multi-drug-resistant TB or extensively drug-resistant TB has been another issue in TB.

The epidemiological studies revealed that only 10 to 30% of people who exposed Mtb are infected with Mtb and that 90% or more of the infected people do not develop TB. Only 5% shows the symptoms within 1 year and 95% of the infected individuals are considered to remain infected latently for the long time. Further, only 5% of individuals who have persistently infected Mtb show internal reactivation, i.e., show the overt symptoms the long time later (North and Jung, 2004). These facts indicate that immune responses that are necessary to contain Mtb are induced in the majority of Mtb-infected individuals. Induction of appropriate immune responses against protective Mtb antigens in appropriate stages is necessary for preventing TB. In this chapter, we review the aspect of immune responses and the vaccine strategies against Mtb.

2. Protective immunity against Mtb

2.1 Immune cell effectors against Mtb

Mtb is a facultative intracellular bacterium that survives in phagosomes of alveolar macrophages. In general, effective immune responses against intracellular pathogens are based on the cellular arm (T cells), not on the humoral arm (antibodies) of immune responses (reviewed in Stenger & Modlin, 1999; Kaufmann, 2003). The followings are effective cell subsets that have been considered to be important for protection against Mtb infection.

2.1.1 CD4⁺ T cells

Intracellular bacteria in phagosomes including Mtb are processed via major histocompatibility complex (MHC) class II-mediated antigen processing pathway and antigens of the bacteria are presented to CD4⁺ helper T cells (reviewed in Kaufmann, 2003; Flynn & Chan, 2001; Cooper, 2009). Therefore, CD4⁺ T cells are considered to be the principal effectors against Mtb. Mice that have a deletion in MHC class II or CD4 gene have been shown to be succumbed against Mtb challenge infection (Ladel et al., 1995; Caruso et al., 1999). CD4⁺ T cells are divided to mainly two subsets depending on the difference of cytokines produced, type 1 helper T cells (Th1) and type 2 helper T cells (Th2). Th1 produces interferon (IFN)- γ , tumor necrosis factor (TNF)- α , and/or interleukin (IL)-2, and contribute to macrophage activation or granuloma formation through effects of these cytokines. IFN- γ has been reported to be the most critical for the protective immunity through analyses of mice or humans which have a deletion in genes encoding IFN- γ or the receptor (Cooper et al., 1993; Flynn et al., 1993; Ottenhoff et al., 1998). Therefore, Th1 has been considered to play a pivotal role for protection against Mtb infection. IFN- γ amounts or the number of IFN- γ -producing T cells has been considered to be a relevant marker for induction of a protective immunity against Mtb (Ellner et al., 2000; Walzl et al., 2011), although it is not the unique marker (Agger & Anderesen, 2001). This cytokine is also able to induce inflammation in the lesion, possibly to help aggravating the disease. Th2 produce IL-4, IL-5, and/or IL-10 and contribute to antibody-mediated immune responses or type 1 allergy development. Therefore, Th2 are considered to have inhibitory effects for protective immunity against Mtb.

2.1.2 CD8⁺ T cells

Theoretically, CD4⁺ T cells are major effector cells against phagosome-localized pathogens. However, CD8⁺ T cells also have been shown to play an important role in protective immunity against Mtb by analysis of Mtb infection experiments to mice that have deficiency in β 2-microglobulin gene critical for MHC class I expression (Flynn et al., 1992; Ladel et al., 1995). Mtb are reported to be cross-presented to CD8⁺ T cells via MHC class I antigen presentation pathway. Kaufmann's group reported that Mtb-infected macrophages induce apoptotic process and then cross-presentation via apoptotic vesicles (Winau et al., 2006). The process may lead to induction of antigen-specific CD8⁺ T cells. van Pinxteren and colleagues (2000) reported that CD8⁺ T cells are particularly important in protective immunity at the latent phase of TB.

CD8⁺ T cells contribute to protective immunity against Mtb in the following mechanisms (Smith & Duckrell, 2000; Kaufmann & Flynn, 2005). (1) Secretion of cytokines such as IFN- γ and TNF- α . IFN- γ production is essential for CD8⁺ T-cell mediation of protective immunity against Mtb (Tascon et al., 1998). (2) Lysis of infected host cells through perforin and granzyme B secretion. (3) Direct killing of bacteria infected through granulysin secretion (Stenger et al., 1997). Stegelmann and colleagues (2005) showed that a subset of CD8⁺ T cells coordinately expresses CC chemokine ligand 5 (CCL5, RANTES), perforin and granulysin, attracts Mtb-infected macrophages and kill the intracellular Mtb (Stegelmann et al., 2005).

2.1.3 Th17 cells

Th17 is a subtype of CD4⁺ T cells and produce IL-17. Th17 promote migration of Th1, neutrophils, and monocytes to TB lesion in the presence of chemokines and contribute to protective immunity against Mtb (Khader et al., 2007).

2.1.4 CD1-restricted T cells

A subset of T cells is antigen-presented through CD1 molecules, not through conventional MHC class I (Ia) or II molecules. Genes encoding CD1 molecules are mapped outside of MHC and are less polymorphic than conventional MHC genes. CD1-restricted T cells have been reported to recognize glycolipids in mycobacterial cell wall such as mycolic acid (Beckman et al., 1994).

2.1.5. $\gamma\delta$ T cells

Most CD4⁺ and CD8⁺ T cells express T-cell receptors of α and β protein chains. A minor subset of T cells expresses T-cell receptor of γ and δ protein chains ($\gamma\delta$ T cells). $\gamma\delta$ T cells tend to distribute in epithelial tissues and contribute to early protection against pathogens invading through epithelium. The phosphoantigen-specific $\gamma\delta$ T cells (V γ 2V δ 2⁺) displayed major expansion during BCG infection and a clear memory-type response after BCG reinfection in a macaque model (Shen et al., 2002)..

2.1.6 NK cells

NK cells have been associated with early resistance against Mtb (Junqueira-Kipnis et al., 2003). NK cells increased in the lung after aerosol infection of Mtb and produce IFN- γ and perforin. But in vivo NK cell depletion experiment had no influence on bacterial load within the lungs in mouse system, suggesting that NK cells do not play essential roles in early stage of Mtb infection.

2.1.7 Regulatory T cells

Regulatory T cells (Treg) are composed of a subset of T cells that express Foxp3 transcription factor and inhibit effector T-cell responses by both cell-to-cell direct contact and secretion of inhibitory cytokines such as IL-10 or transforming growth factor (TGF)- β . They also constitutively express CD25 molecule, α chain protein of the high affinity IL-2 receptor. So, this T-cell subset can be deleted in vivo with injection of anti-CD25 monoclonal antibody and the depletion experiments confirmed that it has been shown to be critical for prevention of autoimmunity and graft rejection. Treg have been reported to be induced in Mtb-infected mice and humans and this cell subset is considered to be important for the persistence of Mtb infection (Kursar et al., 2007).

2.1.8 Antibodies

In general, humoral immunity does not contribute to induction of the protective immunity against Mtb. However, antibodies specific for heparin-binding haemagglutinin (HBHA) and arabinomannan are reported to contribute to reduce the bacterial load in lung (Teitelbaum et

al., 1998; Pethe et al., 2001). Antibodies specific for antigens presented on the surface of Mtb may have some effect to prevent invading Mtb into the host cells.

2.2 Protective antigens of Mtb

The analysis of genome of Mtb H37Rv strain reveals that 3,985 open reading frames exist in the genome (Cole et al., 1998). Since the report, DNA vaccines are possible to be constructed through the genome information. Information of mycobacterial genes and proteins is available from several comprehensive databases (e.g., The Pasteur Institute TubercuList [<http://genolist.pasteur.fr/tuberculist/>], The Institute for Genomic Research (TIGR) Comprehensive Microbial Resource (CMR) [<http://cmr.tigr.org/tigr-scripts/CMR/CmrHomePage.cgi>]). The most important issue in developing effective TB vaccines is to clarify which genes or gene products are important for the protective immunity against Mtb. The fact that viable Mtb, but not killed Mtb, can induce the protective immunity (Orme, 1988) leads to the speculation that mainly secretory proteins would be the protective antigens. In fact, the majority of the target antigens of the cellular arm of immunity has been reported to be secretory or cell-membrane proteins (Andersen, 1994). Representative protective antigens of Mtb have been clarified by analyses of T-cell responses against protein fractions separated with the electrophoresis analyses (Belisle et al., 2005). The followings are the representative protective antigens of Mtb reported.

2.2.1 Antigen 85 complex proteins

Antigen 85 (Ag85) complex proteins are mycobacterial major secreted proteins of 30 to 32 kDa. The proteins have mycolyl transferase function that is necessary for synthesis of lipid components of mycobacterial cell wall and fibronectin-binding function (Wiker & Harboe, 1992; Belisle et al., 1997). Ag85 complex proteins are composed of Ag85A (p32A), Ag85B (p30, MPT59, α antigen), and Ag85C protein. These proteins are well conserved in *Mycobacterium* genus. MPT51 protein has some homology to these proteins (Nagai et al., 1991; Ohara et al., 1995) and has been shown to be a protective antigen (Miki et al., 2004).

2.2.2 Low-molecular-mass secretory proteins

Low-molecular-mass proteins (less than 20 kDa) in Mtb culture fluid proteins (CFPs) have been reported to be major antigens that evoke T-cell responses (Boesen et al., 1995; Demissie et al., 1999). Among a variety of low-molecular-mass secreted proteins, early secreted antigenic target 6-kDa protein (ESAT6) and culture fluid protein 10 (CFP10) have been well studied (Berthet et al., 1998). Recently, ESAT6 and CFP10 proteins are widely used in whole blood IFN- γ release assays for TB diagnosis (Andersen et al., 2000) (QuantIFERON® TB Gold; Cellestis, Ltd., Carnegie, Victoria, Australia).

2.2.3 Heat shock proteins

A variety of heat shock proteins have been shown to be targets for antibodies and T cells in murine and human systems. Among them, heat shock protein 65 (Hsp65) is a major stress protein Mtb produces in macrophage cells. Mtb Hsp65 protein has more than 50% homology with *Escherichia coli* GroEL or human Hsp60 protein (Lee & Horwitz, 1995). Heat

shock proteins have been shown to be expressed in Mtb in macrophages and induce protective immune responses.

2.2.4 Dormant phase proteins

Aforementioned proteins are expressed mainly in acute phase of TB. A different set of genes are expressed in late infection phase or chronic (dormant) phase of TB. DosR regulon is a unit of genes composed of 48 genes, the expression of which is regulated by DosR (Rv3133c). DosR regulon proteins are the major proteins expressed in chronic (dormant) phase of TB (Karalouis et al., 2004). HspX protein (Rv2031c) is one of the immunodominant antigens belong to DosR regulon proteins. It plays an important role in slowing the growth of Mtb as *hspX* gene-deleted Mtb mutants showed increased growth both in mice and in macrophages (Hu et al., 2006). T-cell responses specific for HspX were found in latent Mtb infection (Demissie et al., 2006). In addition, mycobacterial DNA-binding protein-1 (MDP1) has been shown to be expressed in the late phase of TB and induce humoral and cellular immune responses (Matsumoto et al., 2005; Suzuki et al., 2010). Analysis of dormant phase proteins is critical for development of therapeutic TB vaccines against persistent Mtb infection.

2.3 T-cell epitopes of Mtb proteins

T-cell epitopes are the peptides in antigenic proteins that bind to MHC molecules on antigen-presenting cells. In other words, T-cell epitopes are the peptides that stimulate T cells through the MHC-T-cell receptor interaction.




Fig. 1. Schematic diagram for identification of T-cell with DNA immunization

Identification of T-cell epitopes in Mtb antigens is indispensable for accurate analysis of T-cell responses against Mtb antigens with specific MHC tetramers or intracellular cytokine staining. We realized that DNA immunization with gene gun bombardment is an excellent method for identification of Mtb T-cell epitopes as it is highly reproducible and efficiently

Antigen	Epitope peptide	MHC restriction	Reactive T cells	References
Ag85B	p30-38 (9-mer)	A*0201	CD8	Tang et al., 2011
	p183-192 (10-mer)	A*0201	CD8	Geluk et al., 2000
	p239-247 (9-mer)	A*0201	CD8	Geluk et al., 2000
	p10-27 (18-mer)	DR3, 52, 53	CD4	Mustafa et al., 2000b
	p19-36 (18-mer)	Promiscuous	CD4	Mustafa et al., 2000b
MPT51	p91-108 (18-mer)	Promiscuous	CD4	Mustafa et al., 2000b
	p51-70 (10-mer)	A*0201	CD8	Aoshi et al., 2008
Hsp65	p191-202 (12-mer)	DR4 (Promiscuous)	CD4	Wang et al., 2009
	p369-377 (19-mer)	A*0201	CD8	Charo et al., 2001
ESAT6	p3-13 (11-mer)	DR3	CD4	Geluk et al., 1992
	p72-95 (24-mer)	DR52, DQ2	CD4	Mustafa et al., 2000a
HspX (16kDa Protein)	p21-29 (9-mer)	A*0201	CD8	Caccamo et al., 2002
	p120-128 (9-mer)	A*0201	CD8	Caccamo et al., 2002
(DosR regulon)	p91-105 (15-mer)	A*0201	CD8	Geluk et al., 2007
	p31-50 (20-mer)	DR3	CD4	Geluk et al., 2007
Rv1733c (DosR regulon)	p161-169 (9-mer)	A*0201	CD8	Commandeur et al., 2011
Rv1733c	p181-189 (9-mer)	A*0201	CD8	Commandeur et al., 2011
Rv2029c (DosR regulon)	p161-169 (9-mer)	A*0201	CD8	Commandeur et al., 2011

Table 1. Human T-cell epitopes of Mtb antigens (examples)

induces T-cell responses (Yoshida et al., 2000). Therefore, we have used gene gun DNA immunization method for identification of CD8⁺ and CD4⁺ T-cell epitopes of Mtb antigens (Fig. 1). After immunization with plasmid DNA encoding Mtb antigens, immune spleen cells were examined for their IFN- γ responses to overlapping peptides covering full-length Mtb antigens by measuring IFN- γ levels by enzyme-linked immunosorbent assay (ELISA) or by counting the numbers of IFN- γ -secreting cells by enzyme-linked immunospot assay (ELISPOT). We combined these methods with computer algorithms to predict T-cell epitopes. T-cell epitope prediction algorithm programs we used are as follows. They are able to access through their websites. (1) SYFPEITHI Epitope program (<http://www.syfpeithi.de/>) (Rammensee et al., 1999), (2) the National Institutes of Health Bioinformatics and Molecular Analysis Section (BIMAS) HLA Peptide Binding Predictions (http://bimas.dcrt.nih.gov/cgi-bin/molbio/ken_parker_comboform) (Parker et al., 1994), RANKPEP MHC binding peptide prediction algorithm (<http://immunax.dfc.harvard.edu/Tools/rankpep.html>) (Reche et al., 2004), and (4) ProPred HLA-DR binding peptide prediction algorithm (<http://www.imtech.res.in/raghava/propred/>) (Singh & Raghava, 2001). These programs are helpful for narrowing down the amino acid regions of T-cell epitopes. However, the algorithms are still not perfect for exact identification of bona fide T-cell epitopes. A peptide that shows the highest score in these algorithms is not necessarily the best T-cell epitope. Experimental validation is definitely necessary to determine actual T-cell epitopes. A variety of

T cell epitopes of Mtb antigens have been reported. A comprehensive analysis of T-cell epitope data regarding *Mycobacterium* genus in the immune epitope database (IEDB; <http://immuneepitope.org>) was performed (Blythe et al., 2007). Huygen and colleagues have reported identification of murine T-cell epitopes of Ag 85 family proteins (Ag85A, Ag85B, and Ag85C) (Denis et al., 1998, D'Souza, et al., 2003) using intramuscular DNA immunization. We have used gene gun DNA immunization method for identification of murine CD8⁺ and CD4⁺ T-cell epitopes of Mtb antigens including MPT51 (Suzuki et al., 2004), MDP1 (Suzuki et al., 2010), and low-molecular-mass secretory antigens (CFP11, CFP17, and TB18.5) (Eweda et al., 2010).

In addition to murine T-cell epitopes, human T-cell epitopes have been reported (some examples are shown in Table 1). HLA-A02 is the most frequent HLA molecule in Caucasians and HLA-A*0201 represents the most frequent allele. HLA-A*0201-restricted CD8⁺ T-cell epitopes have been identified in a variety of antigens including those derived from cancers, viruses, bacteria, and protozoan. Mtb-derived HLA-A*0201-restricted CD8⁺ T-cell epitopes have been reported, including epitopes in Ag85A (Smith et al., 2000), Ag85B (Geluk et al., 2000), ESAT6 (Lalvani et al., 1998), and Hsp65 (Charo et al., 2001).

T-cell epitope (10-mer)	Position										
	1	2	3	4	5	6	7	8	9	10	
Anchor residues	L, M					L, V, I					
MPT51 p53-62	T	L	A	G	K	G	I	S	V	V	Aoshi et al., 2008
Ag85B p143-152	F	I	Y	A	G	S	L	S	A	L	Geluk et al., 2000
T-cell epitope (9 mer)	Position										
	1	2	3	4	5	6	7	8	9		
Anchor residues	L, M					L, V, I					
Ag85B p30-38	G	L	A	G	G	A	A	T	A	Tang et al., 2011	
Ag85B p183-192	K	L	V	A	N	N	T	R	L	Geluk et al., 2000	
Ag85B p239-247	G	L	A	G	G	A	A	T	A	Geluk et al., 2000	
Hsp65 p369-337	K	L	A	G	G	V	A	V	I	Charo et al., 2001	
HspX (DosR reg) p13-21	L	F	A	A	F	P	S	F	A	Caccamo et al., 2002	
HspX (DosR reg) p120-128	G	I	L	T	V	S	V	A	V	Caccamo et al., 2002	
Rv1733c (DosR reg) p161-169	I	A	D	A	A	L	A	A	L	Commandeur et al., 2011	
Rv1733c (DosR reg) p181-189	A	L	L	A	L	T	R	A	I	Commandeur et al., 2011	
Rv2029c (DosR reg) p314-322	E	L	A	A	E	P	T	E	V	Commandeur et al., 2011	

Table 2. HLA-A*0201-restricted T-cells epitopes od Mtb antigens (examples)

Most HLA-A*0201-restricted T-cell epitopes were nonamer peptides (Falk et al., 1991, Parker, 1994), but some epitopes were decamer peptides. We reported an immunodominant HLA-A*0201-restricted T-cell epitope in MPT51 antigen (Aoshi et al., 2008; Tables 1, 2). Main anchor amino acid positions are, position 2 (Leu) and position 9 (Val), which were conserved in MPT51 p53-62 (TLAGKGISVV) (Table 2). MPT51 p53-62 decamer peptide was capable of binding to HLA-A*0201 and of stimulating CD8⁺ T cells of HLA-A*0201-transgenic mice, but MPT51 p53-61 nonamer was not. The conformational and electrostatic differences between the nonamer and the decamer would affect their binding affinity to HLA-A*0201 molecule and following T-cell responses. Ruppert and colleagues (1993) studied in detail the role of different amino acid residues on each position of nonamer or decamer peptides for binding to HLA-A*0201 molecule. They suggested that nonamer or decamer peptide has different preference of amino acid residues for binding to HLA-A*0201 molecule. They showed that, for example, Tyr, Phe, Trp residues at positions 1, 3, and 5 in nonamer peptides, Gly residues at positions 4 and 6 in decamer peptides are preferable for binding to HLA-A*0201. According to their speculation, MPT51 p53-62 peptide seems to have better A*0201 binding features than MPT51 p53-61 peptide (Gly residues at positions 4 and 6 in MPT51 p53-62 peptide are suggested to be associated with good A*0201 binding). Interestingly, MPT51 p21-29 peptide (FLAGGPHAV) was not immunogenic in terms of IFN- γ production and cytolytic ability although the peptide showed high affinity to HLA-A*0201 as predicted by MHC binding algorithms (Aoshi et al., 2008). Previous reports showed a strong association between immunodominance and HLA binding affinity (Geluk et al., 1998). But, binding of peptides to the restricted MHC molecules is a prerequisite for T-cell epitopes, but all the peptides which show high affinity binding for MHC molecules are not necessarily immunodominant epitopes.

3. Vaccine strategies against Mtb

3.1 Recombinant BCG vaccines

Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the only approved attenuated live vaccine to date against TB. Original BCG strain was reported approximately ninety years ago (1921) by Calmette and Guérin (Bloom & Fine, 1994). Despite the fact that BCG is among the most widely used vaccine throughout the world since then, TB still poses a serious global health threat. Whereas BCG is believed to protect newborns and young children against early manifestations of TB (Rodrigues et al., 1993), its efficacy against pulmonary TB in adults is still a subject of debate (Bloom & Fine, 1994; Andersen & Doherty, 2005) and was reported to wane with time since vaccination (Sterne et al., 1998). Variable levels of the protective efficacy ranging from 0 to 80% have been reported in different studies (Fine, 1995). Moreover, the viable nature of BCG makes it partly unsafe in case of immunocompromised people such as HIV-infected individuals. This highlights the need to develop more effective, safe and reliable vaccines against TB (Kaufmann, 2010).

To improve the immunoreactivity of conventional BCG vaccines, a variety of recombinant BCG (rBCG) vaccines have been tried and evaluated for the protective efficacy (Stover et al., 1991). One of the problems of conventional BCG vaccines in induction of protective immune responses is that BCG is not effective for induction of CD8⁺ T-cell responses compared with Mtb. BCG is less effective in MHC class I-mediated antigen presentation, which is prerequisite for CD8⁺ T-cell induction (Mazzaccaro et al., 1996). To improve CD8⁺ T-cell

responses of BCG, Kaufmann and colleagues reported recombinant BCG (rBCG) introduced with listeriolysin O (LLO) gene derived from *Listeria monocytogenes* (Hess et al., 1998). *L. monocytogenes* escapes from the phagosomes into the cytoplasm shortly after infection into host macrophage cells. LLO, a thiol-activated cytolysin, has membrane-disrupting capability and plays a pivotal role in this process. The rBCG expressing LLO was reported to improve MHC class I-mediated antigen presentation of co-phagocytosed ovalbumin, suggesting that LLO endows BCG with an improved capacity to stimulate CD8⁺ T cells. Further, the same group constructed urease C gene (*ureC*)-disrupted rBCG expressing LLO (Grode et al., 2005). Mycobacterial *ureC* increases pH value in the phagosome. The *ureC* deficiency induces low pH value in the phagosome, helping the LLO enzyme activity (to disrupt phagosome membranes), which leads enhancement of MHC class I-mediated CD8⁺ T-cell responses.

Another promising rBCG is BCG overexpressing Ag85B protein (Horwitz et al., 2000). Ag85B is a major mycobacterial secreted protein and has been shown to be a protective antigen. Even though BCG does have endogenous Ag85B, overexpression of Ag85B in BCG was further enhanced the protective ability. In addition to these rBCG, attenuated auxotroph strains of Mtb have been examined (Guleria et al., 1996; Sambandamurthy et al., 2006; Larsen et al., 2009).

3.2 DNA Vaccination against TB

Many reports on DNA vaccination against Mtb have been published since 1996 (Huygen et al., 1996, Tascon et al., 1996). So far, a variety of Mtb antigen genes have been used for DNA vaccines, which include Hsp 65, Hsp 70, Ag85A, Ag85B, and ESAT6 (reviewed in Huygen, 2003 for early studies). DNA immunization with genes encoding dormancy regulon-encoded proteins has also been examined (Roupie et al., 2007). DNA immunization with naked DNA has been shown to efficiently induce cellular as well as humoral immune responses. DNA vaccines in most of these reports use needle injection through intramuscular or intradermal routes although some studies used gene gun (Sugawara et al., 2003). The DNA immunization with needle injection tends to raise predominant Th1 responses which are indispensable for induction of the protective immunity. On the other hand, gene gun DNA immunization is apt to produce "mixed type" (Th1 and Th2; producing IFN- γ and IL-4) T-cell responses which is not necessarily adequate for induction of the protective immunity (Tanghe et al., 2000). The difference is considered to be mainly due to the difference in the amount of antigen produced from the plasmids (high amounts in needle injection and low amounts in gene gun bombardment). Therefore, DNA vaccination with gene gun will need additional factors such as adjuvants for eliciting protective immunity against Mtb (D'Souza et al., 2002; Tollefsen et al., 2002; Li et al., 2006; Zhang et al., 2007).

Naked DNA vaccines have been evaluated as therapeutic TB vaccines as well as prophylactic TB vaccines. Lowrie and colleagues (1999) showed that intramuscular injection of mice with Hsp65 and MPT70 DNA vaccines reduced Mtb numbers in spleens and lungs after Mtb challenge by 1 to two log₁₀ order compared with untreated mice. Further, they showed that three intramuscular injection of Hsp65 DNA vaccine eliminated residual Mtb after chemotherapy (isoniazid and pyrazinamid treatment) and immunosuppressive corticosteroid treatment. However, Orme's group reported that Ag85A DNA vaccine that was shown to induce protective immunity in mice when the vaccine was used as a

prophylactic vaccine, could not give any therapeutic effect on the course of the infection in the lungs in mice earlier infected by Mtb aerosol (Turner et al., 2000). Moreover, they reported that vaccination with DNA encoding hsp60 of *Mycobacterium leprae* induced cellular necrosis throughout the lung granulomas when the DNA was given in a mouse immunotherapeutic model (Taylor et al., 2003). Repique and colleagues (2002) also reported that vaccination with a DNA vaccine cocktail containing ten Mtb antigen genes which had showed significant protective responses in mice could not prevent reactivation of disease in a murine latent TB model. These reports indicate that therapeutic TB vaccines still have room for further studies in terms of safety.

3.3 Improvement in immunization regimen: prime-boost immunization

Evaluation of vaccination has indicated that the repeated injection of the same vaccine has a limitation in terms of its overall immunological effects. Especially, DNA immunization has been reported to induce considerably strong immunological responses in the rodents, but not in the primates including human (Li et al., 1993). Instead of the repeated injection of the same vaccine, the heterologous prime-boost regimen including DNA vaccination, which is primed with naked DNA vaccination and boosted with recombinant viral vectors such as vaccinia virus and adenovirus, has been shown to evoke superior levels of immunity to DNA vaccine or recombinant virus alone (Ramshaw & Ramsay, 2000). The relatively low-level but persistent expression of immunogenic proteins in vivo by naked DNA vaccines has been suggested to be important for priming immunological responses and inducing enhanced cellular immunity (Ramshaw & Ramsay, 2000).

A variety of prime-boost regimens have been examined for Mtb infection (McShane & Hill, 2005). Many investigators examined the regimens in which priming with DNA vaccines and boosting with other immunization strategies. Feng and colleagues (2001) showed that priming with Ag85B DNA vaccine and boosting with BCG vaccine strengthened protective immunity against Mtb induced by BCG vaccine alone in mice. Skinner and colleagues (2003) also reported that priming with ESAT6 and Ag85A DNA vaccines and boosting with BCG vaccine enhanced specific IFN- γ production from immune splenocytes compared with that by the DNA vaccine or BCG vaccine alone in mice. Ferraz and colleagues (2004) used DNA vaccines encoding mycobacterial Hsp70, Hsp65, and Apa antigens as priming vaccine and showed that the DNA vaccines enhanced BCG boosting effects. Romano and colleagues (2006) showed that immunization of BALB/c mice with Ag85A DNA vaccine first and boosting with BCG vaccine induced stronger protective immunity against Mtb challenge than that by Ag85A DNA vaccine alone. These results demonstrated that DNA vaccine priming and BCG vaccine boosting enhanced immune responses induced by BCG vaccine alone.

The regimens in which BCG vaccine was used as a priming vaccine also have been tried. As the BCG vaccine has been injected to people all over the world, this regimen seems to be reasonable. Derrick and colleagues (2004) showed that a polyvalent DNA vaccine encoding an ESAT6-Ag85B fusion protein protects mice against a primary Mtb infection and boosts BCG-induced protective immunity. Priming with BCG vaccine and intranasal boosting with MVA85A in mice enhanced Ag85A-specific CD4⁺ and CD8⁺ T-cell responses and strengthened protective immunity against aerosol Mtb challenge infection in mice (Goonetilleke et al., 2003). This regimen was reported in humans. McShane and colleagues

(2004) reported that in volunteers who had been vaccinated 0.5 to 38 years previously with BCG, vaccination with MVA85A induced substantially higher levels of antigen-specific IFN- γ -secreting T cells and that at 24 weeks after vaccination, these levels were 5 to 30 times greater than in vaccinees administered a single BCG vaccination.

3.4 Ongoing tuberculosis vaccine projects

A variety of TB vaccines have been evaluated (reviewed in Hoft, 2008; Kaufmann, 2010a, 2010b). WHO have showed a list of TB vaccine candidates (TB vaccine pipeline: <http://www.stoptb.org/retooling/>). These TB vaccine strategies are based on the prime-boost regimens and the vaccine candidates are categorized into three vaccine groups, namely, (1) priming vaccines, (2) boosting vaccines, and (3) therapeutic vaccines after Mtb infection. Some of vaccine candidates that have been ongoing are shown in Table 3.

Vaccine	Source	Explanation	References
Priming Vaccines			
rBCG30	UCLA (M. Horwitz)/NIAID	Ag85B recombinant BCG	Horwitz et al., 2000
rBCG $\Delta ureC:hly$ (VPM1002)	Max Planck Inst. (S. Kaufmann) /VPM/TBVI	Listeriolysin O (LLO) recombinant BCG	Grode et al., 2005, Tchilian et al., 2009
mc ^c 6220, 6221, 6222, 6231	Albert Einstein College of Med.	$\Delta lysA\Delta panCD$ (lysin/pantoic acid-erquiring attenuated <i>M. tuberculosis</i>)	Sambandamurthy et al., 2006
Booster Vaccines			
MVA85A/AERAAS-485	Oxford/Isis/Aeras/Emmertent	Ag85A recombinant Vaccinia Virus	McShane et al., 2001, Goonetilleke et al., 2003, McShane et al., 2004, Scriba et al., 2010
AERAS-402/Crucell Ad35	Crucell/Aeras	Ag85A, Ag85B, TB10.4 recombinant Adenovirus type 35	Radosević et al., 2007 Abel et al., 2010
GSK M72	GSK/Aeras	PPE family protein Rv1196-Rv0125 fusion protein + AS01 adjuvant	Skeikey et al., 2004
SSI Hybrid I	Statens Serum Inst. (SSI)	Ag85B-ESAT6 fusion protein+IC31 adjuvant	Olsen et al., 2004 Aagaard et al., 2011
SSI HyVac 4/AERAS-404	SSI/Sanori Pasteur/ Intercell/Aeras	Ag85B-TB10.4 fusion protein+IC31 adjuvant	Dietrich et al., 2005, Skeikey et al., 2010
rBCG30 HVJ-liposome/ Hsp65 DNA+IL-12 DNA	UCLA (M. Horwitz)/NIAID Kinki-chuo Chest Medical Center (Okada)	Ag85B recombinant BCG Hsp65 DNA+IL-12 DNA + HVJ-liposome	Horwitz et al., 2000 Yoshida et al., 2006
Therapeutic Vaccines			
MVA85A	Oxford	Ag85A recombinant Vaccinia Virus	McShane et al., 2001, Goonetilleke et al., 2003, McShane et al., 2004
Hsp65 DNA vaccine	Cardiff Univ. (D. Lowrie)	hsp65 DNA Vaccine	Lowrie et al., 1999

Table 3. TB vaccine candidates (According to WHO TB Vaccine Pipeline)

BCG vaccines and rBCG vaccines are considered to be priming vaccines. For priming vaccines, BCG overexpressing Ag85B (rBCG30) and *ureC*-deleting BCG expressing listeriolysin O ($\Delta ureC hly^+$ BCG) have been evaluated. For booster vaccines, Ag85A recombinant vaccinia virus (MVA85A), Ag85B-ESAT6 fusion protein with adjuvant (SSI Hybrid I), and Ag85B-TB10.4 fusion protein with adjuvant (SSI HyVac4/AERAS-404) have been examined. MVA85A and Hsp65 DNA vaccine are candidate TB vaccine are candidate therapeutic TB vaccines. Human studies using the prime-boost regimens by these TB vaccine candidates have been publishing. Tchilian and colleagues (2009) reported that priming with $\Delta ureC hly^+$ BCG and boosting with MVA85A induced protective immunity against Mtb infection in mice. The protective effects were much higher in $\Delta ureC hly^+$ BCG vaccination than that in parental BCG vaccination. MVA85A boost immunization enhanced

Ag85A-specific T-cell responses, but did not affect bacterial numbers in the lung after Mtb aerosol infection. Scriba and colleagues (2010) reported that vaccination with MVA85A in healthy adolescents and children from a TB endemic region, who received BCG at birth, is safe and induces polyfunctional CD4⁺ T cells co-expressing IFN- γ , TNF- α , and IL-2. Further, Abel and colleagues (2010) reported that vaccination with AERAS-402 (Adenovirus type 35 expressing a fusion protein created from the sequences of Ag85A, Ag85B, and TB10.4) is safe and immunogenic in healthy South African BCG-vaccinated adults.

4. Conclusion

Mtb, a causative agent of TB, is a unique facultative intracellular bacterium. The cellular immunity is essential for protection against Mtb. The main effectors are type 1 CD4⁺ T cells and CD8⁺ T cells. IFN- γ produced from them has been considered to be important as biomarker of TB. Induction of appropriate immune responses against protective Mtb antigens in appropriate stages is necessary for preventing TB. Identification of protective Mtb antigens and the T-cell epitopes are critical for clarification of kinetics of TB and development of effective TB vaccines. A variety of TB vaccine strategies have been examined including rBCG and DNA vaccines. Prime-boost strategies with combination of different TB vaccines are promising for prophylactic TB vaccines. Therapeutic TB vaccines for latent TB have also been examined.

5. References

- Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. (2011). A multistage tuberculosis vaccine that confers efficient protection before and after exposure. *Nature Medicine*, Vol.17, No. 2, (February 2011), pp. 189-194, ISSN 1078-8956
- Abel, B., Tameris, M., Mansoor, N., Gelderbloem, S., Hughes, J., Abrahams, D., Makhethe, L., Erasmus, M., de Kock, M., van der Merwe, L., Hawkridge, A., Veldsman, A., Hatherill, M., Schirru, G., Pau, M. G., Hendriks, J., Weverling, G.J., Goudsmit, J., Sizemore, D., McClain, J.B., Goetz, M., Gearhart, J., Mahomed, H., Hussey, G. D., Sadoff, J. C. & Hanekom, W. A. (2010). The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4⁺ and CD8⁺ T cells in adults. *American Journal of Respiratory and Critical Care Medicine*, Vol. 181, No. 12, (June 2010), pp. 1407-1417, ISSN 1073-449X
- Agger, E. M. & Andersen, P. (2001). Tuberculosis subunit vaccine development: on the role of interferon- γ . *Vaccine*, Vol. 19, No. 17-19, (March 2001), pp. 2298-2302, ISSN 0264-410X
- Andersen, P. (1994). Effective vaccination of mice against *Mycobacterium tuberculosis* infection with a soluble mixture of secreted mycobacterial proteins. *Infection and Immunity*, Vol. 62, No. 6, (June 1994), pp. 2536-2544, ISSN 0019-9567
- Andersen, P & Doherty, T.M. (2005). The success and failure of BCG – implications for a novel tuberculosis vaccine. *Nature Reviews Microbiology*, Vol.3, No. 8, (August 2005), pp. 656-662, ISSN 1740-1526
- Andersen, P., Munk, M. E., Pollock, J. M. & Doherty, T. M. (2000). Specific immune-based diagnosis of tuberculosis. *Lancet*, Vol. 356, (September 2000), pp. 1099-1104, ISSN 0140-6736

- Aoshi, T., Nagata, T., Suzuki, M., Uchijima, M., Hashimoto, D., Rafiei, A., Suda, T., Chida, K. & Koide, Y. (2008). Identification of an HLA-A*0201-restricted T-cell epitope on the MPT51 protein, a major secreted protein derived from *Mycobacterium tuberculosis*, by MPT51 overlapping peptide screening. *Infection and Immunity*, Vol.76, No. 4, (April 2008), pp. 1565-1571, ISSN 0019-9567
- Beckman, E. M., Porcelli, S. A., Morita, C. T., Behar, S. M., Furlong, S. T. & Brenner, M. B. (1994). Recognition of a lipid antigen by CD1-restricted $\alpha\beta^+$ T cells. *Nature*, Vol. 372, No. 6507, (December 1994), pp. 691-694, ISSN 0028-0836
- Belisle, J. T., Braunstein, M., Rosenkrands, I. & Andersen, P. (2005). The proteome of *Mycobacterium tuberculosis*. In: *Tuberculosis and the tubercle bacillus*, S. T. Cole, K. D. Eisenach, D. N. McMurray & W. R. Jacobs Jr (Eds.), pp. 235-260, ASM Press, ISBN 1-55581-295-3, Washington, DC.
- Belisle, J. T., Vissa, V. D., Sievert, T., Takayama, K., Brennan, P. J. & Besra, G. S. (1997). Role of the major antigen of *Mycobacterium tuberculosis* in cell wall biogenesis. *Science*, Vol.276, No. 5317, (May 1997), pp. 1420-1422, ISSN 0036-8075
- Berthet, F. X., Rasmussen, P. B., Rosenkrands, I., Andersen, P. & Gicquel, B. (1998). A *Mycobacterium tuberculosis* operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). *Microbiology*, Vol. 144, (November 1998), pp. 3195-3203, ISSN 0026-2617
- Bloom, B.R. & Fine, P.E.M. (1994). The BCG experience: implications for future vaccines against tuberculosis. In: *Tuberculosis: pathogenesis, protection, and control*, Bloom (Ed.), pp. 531-557, ASM Press, ISBN 1-55581-072-1, Washington, DC.
- Blythe, M. J., Zhang, Q., Vaughan, K., de Castro Jr, R., Salimi, N., Bui, H. H., Lewinsohn, D. M., Ernst, J. D., Peters, B. & Sette, A. (2007). An analysis of the epitope knowledge related to Mycobacteria. *Immunome Research*, Vol. 3, No. 10, (December 2007), online, ISSN1745-7580.
- Boesen, H., Jensen B. N., Wilcke, T. & Andersen, P. (1995). Human T-cell responses to secreted antigen fractions of *Mycobacterium tuberculosis*. *Infection and Immunity*, Vol. 63, No. 4, (April 1995), pp. 1491-1497, ISSN 0019-9567
- Caccamo, N., Milano, S., Sano, C., Cigna, D., Ivanyi, J., Krensky, A. M., Dieli, F. & Salerno, A. (2002). Identification of epitopes of *Mycobacterium tuberculosis* 16-kDa protein recognized by human leukocyte antigen-A*0201 CD8⁺ T lymphocytes. *Journal of Infectious Diseases*, Vol. 186, No. 7, (October 2002), pp. 991-998, ISSN 0022-1899
- Caruso, A. M., Serbina, N., Klein, E., Triebold, K., Bloom, B. R. & Flynn J. L. (1999). Mice deficient in CD4 T cells have only transiently diminished levels of IFN- γ , yet succumb to tuberculosis. *Journal of Immunology*, Vol. 162, No. 9, (May 1999), pp. 5407-5416, ISSN 0022-1767
- Charo, J., Geluk, A., Sundbäck, M., Mirzai, B., Diehl, A. D., Malmberg, K.-J., Achour, A., Huriguchi, S., van Meijgaarden, K. E., Drijfhout, J.-W., Beekman, N., van Veelen, P., Ossendorp, F., Ottenhoff, T. H. M. & Kiessling, R. (2001). The identification of a common pathogen-specific HLA class I A*0201-restricted cytotoxic T cell epitope encoded within the heat shock protein 65. *European Journal of Immunology*, Vol.31, No. 12, (December 2001), pp. 3602-3611, ISSN 0014-2980
- Cole, S. T., Brosch, R., Parkhill, J., Garunier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglemeier, K., Gas, S., Barry III, C. E., Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S.,

- Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Krogh, A., McLean, J., Moule, S., Murphy, L., Oliver, K., Osborne, J., Quail, M. A., Rajandream, M.-A., Rogers, J., Rutter, S., Seeger, K., Skelton, J., Squares, R., Squares, S., Sulston, J. E., Taylor, K., Whitehead, S. & Barrell, B. G. (1998). Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature*, Vol.393, No. 6707, (November 1998), pp. 537-544, ISSN 0028-0836
- Commandeur, S., Lin, M. Y., van Meijgaarden, K. E., Friggen, A. H., Franken, K. L. M. C., Drijfhout, J. W., Korsvold, G. E., Oftung, F., Geluk, A. & Ottenhoff, T. H. M. (2011). Double- and monofunctional CD4⁺ and CD8⁺ T-cell responses to *Mycobacterium tuberculosis* DosR antigens and peptides in long-term latently infected individuals. *European Journal of Immunology*, in press, ISSN 0014-2980
- Cooper, M. A. (2009). Cell-mediated immune responses in tuberculosis. *Annual Review of Immunology*, Vol.27, pp. 393-422, ISSN 0732-0582
- Cooper, M. A., Dalton, D. K., Stewart, T. A., Griffin, J. P., Russell, D. G. & Orme, I. M. (1993). Disseminated tuberculosis in interferon γ gene-disrupted mice. *Journal of Experimental Medicine*, Vol. 178, No. 6, (December 1993), pp. 2243-2247, ISSN 0022-1007
- Demissie, A., Leyten, E. M., Abebe, M., Wassie, L., Aseffa, A., Abate, G., Fletcher, H., Owiafe, P., Hill, P. C., Brookes, R., Rook, G., Zumla, A., Arend, S. M., Klein, M., Ottenhoff, T. H., Andersen, P., Doherty, T. M. & VACSEL Study Group. (2006). Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with *Mycobacterium tuberculosis*. *Clinical and Vaccine Immunology*, Vol.13, No. 2, (February 2006), pp. 179-186, ISSN 1556-6811
- Demissie, A., Ravn, P., Olobo, J., Doherty, T. M., Eguale, T., Geletu, M., Hailu, W., Andersen, P. & Britton, S. (1999). T-cell recognition of *Mycobacterium tuberculosis* culture filtrate fractions in tuberculosis patients and their household contacts. *Infection and Immunity*, Vol. 67, No. 11, (November 1999), pp. 5967-5971, ISSN 0019-9567
- Denis, O., Tanghe, A., Palfliet, K., Jurion, F., van den Berg, T.-P., Vanonckelen, A., Ooms, J., Saman, E., Ulmer, J. B., Content, J. & Huygen, K. (1998): Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4⁺ and CD8⁺ T-cell epitopic repertoire broader than that stimulated by *Mycobacterium tuberculosis* H37Rv infection. *Infection and Immunity*, Vol.66, No. 4, (April 1998), pp.1527-1533, ISSN 0019-9567
- Derrick, S. C., Yang, A. L. & Morris, S. L. (2004). A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with *Mycobacterium tuberculosis* and boosts BCG-induced protective immunity. *Vaccine*, Vol.23, No. 6, (December 2004), pp. 780-788, ISSN 0264-410X
- Dietrich, J., Aagaard, C., Leah, R., Olsen, A. W., Stryhn, A., Doherty, T. M. & Andersen, P. (2005). Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. *Journal of Immunology*, Vol.174, No. 10, (May 2005), pp. 6332-6339, ISSN 0022-1767
- D'Souza, S., Rosseels, V., Denis, O., Tanghe, A., De Smet, N., Jurion, F., Palfliet, K., Castiglioni, N., Vanonckelen, A., Wheeler, C. & Huygen, K. (2002). Improved tuberculosis DNA vaccines by formulation in cationic lipids. *Infection and Immunity*, Vol.70, No. 7, (July 2002), pp. 3681-3688, ISSN 0019-9567

- D'Souza, S., Rosseels, V., Romano, M., Tanghe, A., Denis, O., Jurion, F., Castiglione, N., Vanonckelen, A., Palfiliot, K., Huygen, K. (2003). Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from *Mycobacterium tuberculosis*. *Infection and Immunity*, Vol.71, No. 1, (January 2003), pp. 483-493, ISSN 0019-9567
- Ellner, J. J., Hirsch, C. S. & Whalen, C. C. (2000). Correlates of protective immunity to *Mycobacterium tuberculosis* in humans. *Clinical Infectious Diseases*, Vol.30, Suppl. 3, (June 2000), pp. S279-S282, ISSN 1058-4838
- Eweda, G., Suzuki D, Nagata T, Tsujimura K, Koide, Y. (2010). Identification of murine T-cell epitopes on low-molecular-mass secretory proteins (CFP11, CFP17, and TB18.5) of *Mycobacterium tuberculosis*. *Vaccine*, Vol.28, No. 29, (June 2010), pp. 4616-4625, ISSN 0264-410X
- Falk, K., Röttschke, O., Stevanović, S., Jung, G. & H. G. Rammensee, H. G. (1991). Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature*, Vol.351, No. 6324, (May 1991), pp. 290-296, ISSN 0028-0836
- Feng, C. G., Palendira, U., Demangel, C., Spratt, J. M., Malin, A. S. & Britton, W. J. (2001). Priming by DNA immunization augments protective efficacy of *Mycobacterium bovis* Bacille Calmette-Guerin against tuberculosis. *Infection and Immunity*, Vol.69, No. 6, (June 2001), pp. 4174-4176, ISSN 0019-9567
- Ferraz, J. C., Stavropoulos, E., Yang, M., Coade, S., Espitia, C., Lowrie, D. B., Colston, M. J. & Tascon, R. E. (2004). A heterologous DNA priming-*Mycobacterium bovis* BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. *Infection and Immunity*, Vol.72, No. 12, (December 2004), pp. 6945-6950, ISSN 0019-9567
- Fine, P. E. M. (1995): Variation in protection by BCG: implications of and for heterologous immunity. *Lancet*, Vol.346, No. 8986, (November 1995), pp. 1339-1345, ISSN 0140-6736
- Flynn, J. L. & Chan, J. (2001): Immunology of tuberculosis. *Annual Review Immunology*, Vol.19, pp. 93-129, ISSN 0732-0582
- Flynn, J. L., Chan, J., Triebold, K. J., Dalton, D. K., Stewart, T. A. & Bloom, B. R. (1993). An essential role for interferon γ in resistance to *Mycobacterium tuberculosis*. *Journal of Experimental Medicine*, Vol. 178, No. 6, (December 1993), pp. 2249-2254, ISSN 0022-1007
- Flynn, J. L., Goldstein, M. M., Triebold, K. J., Koller, B. & Bloom, B. R. (1992). Major histocompatibility complex class I-restricted T cells are required for resistance to *Mycobacterium tuberculosis* infection. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.89, No. 24, (December 1992), pp. 12013-12017, ISSN 0027-8424
- Geluk, A., Bloemhoff, W., De Vries, R. R. P. & Ottenhoff, T. H. M. (1992). Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. *European Journal of Immunology*, Vol.22, No. 1, (January 1992), pp. 107-113, ISSN 0014-2980
- Geluk, A., Lin, M. Y., van Meijgaarden, K. E., Leyten, E. M., Franken, K. L., Ottenhoff, T. H. & Klein, M. R. (2007). T-cell recognition of the HspX protein of *Mycobacterium tuberculosis* correlates with latent *M. tuberculosis* infection but not with *M. bovis* BCG

- vaccination. *Infeccion and Immunity*, Vol.75, No. 6, (June 2007), pp. 2914-2921, ISSN 0019-9567
- Geluk, A., Taneja, V., van Meijgaarden, K. E., Zanelli, E., Abou-Zeid, C., Thole, J. E., de Vries, R. R., David, C. S. & Ottenhoff, T. H. (1998). Identification of HLA class II-restricted determinants of *Mycobacterium tuberculosis*-derived proteins by using HLA-transgenic, class II-deficient mice. *Proceedings of the National Academy of Science of the United States of America*, Vol. 95, No. 18, (September 1998), pp. 10797-10802, ISSN 0027-8424
- Geluk, A., van Meijgaarden, K. E., Franken, K. L. M. C., Drijfhout, J. W., D'Souza, S., Neeker, A., Huygen, K. & Ottenhoff, T. H. M. (2000). Identification of major epitopes of *Mycobacterium tuberculosis* AG85B that are recognized by HLA-A*0201-restricted CD8⁺ T cells in HLA-transgenic mice and humans. *Journal of Immunology*, Vol.165, No. 11, (December 2000), pp. 6463-6471, ISSN 0022-1767
- Goonetilleke, N. P., McShane, H., Hannan, C. M., Anderson, R. J., Brooks, R. H. & Hill, A. V. S. (2003). Enhanced immunogenicity and protective efficacy against *Mycobacterium tuberculosis* of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. *Journal of Immunology*, Vol.171, No. 3, (August 2003), pp. 1602-1609, ISSN 0022-1767
- Grode, L., Seiler, P., Baumann, S., Hess, J., Brinkmann, V., Eddine, A. N., Mann, P., Goosmann, C., Bandermann, S., Smith, D., Bancroft, G. J., Reyrat, J.-M., van Soolingen, D., Raupach, B. & Kaufmann, S. H. E. (2005). Increased vaccine efficacy against tuberculosis of recombinant *Mycobacterium bovis* bacille Calmette-Guérin mutants that secrete listeriolysin. *Journal of Clinical Investigation*, Vol.115, No. 9, (September 2005), pp. 2472-2479, ISSN 0021-9738
- Guleria, I., Teitelbaum, R., McAdam, R. A., Kalpana, G., Jacobs Jr, W. R. & Bloom, B. R. (1996). Auxotrophic vaccines for tuberculosis. *Nature Medicine*, Vol.2, No. 3, (March 1996), pp. 334-337, ISSN 1078-8956
- Hess, J., Miko, D., Catic, A., Lehmsiek, V., Russell, D. G. & Kaufmann, S. H. (1998). *Mycobacterium bovis* Bacille Calmette-Guérin strains secreting listeriolysin of *Listeria monocytogenes*. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.95, No. 9, (April 1998), pp. 5299-5304, ISSN 0027-8424
- Hoft, D. F. (2008). Tuberculosis vaccine development: goals, immunological design, and evaluation. *Lancet*, Vol. 372, No. 9633, (July 2008), pp. 164-175, ISSN 0140-6736
- Horwitz, M. A., Harth, G., Dillon, B. J. & Masleša-Galić, S. (2000). Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the *Mycobacterium tuberculosis* 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.97, No. 25, (December 2000), pp. 13853-13858, ISSN 0027-8424
- Hu, Y., Movahedzadeh, F., Stoker, N. G. & Coates, A. R. (2006). Deletion of the *Mycobacterium tuberculosis* α -crystallin-like *hspX* gene causes increased bacterial growth in vivo. *Infeccion and Immunity*, Vol.74, No. 2, (February 2006), pp. 861-868, ISSN 0019-9567
- Huygen, K. (2003). On the use of DNA vaccines for the prophylaxis of mycobacterial diseases. *Infeccion and Immunity*, Vol.71, No. 4, (April 2003), pp. 1613-1621, ISSN 0019-9567

- Huygen, K., Content, J., Denis, O., Montgomery, D. L., Yawman, A. M., Deck, R. R., DeWitt, C. M., Orme, I. M., Baldwin, S., D'Souza, C., Drowart, A., Lozes, E., Vandenbussche, P., Van Vooren, J.-P., Liu, M. A. & Ulmer, J. B. (1996). Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. *Nature Medicine*, Vol.2, No. 8, (August 1996), pp. 893-898, ISSN 1078-8956
- Junqueira-Kipnis, A. P., Kipnis, A., Jamieson, A., Juarrero, M. G., Diefenbach, A., Raulet, D. H., Turner, J. & Orme, I. M. (2003). NK cells respond to pulmonary infection with *Mycobacterium tuberculosis*, but play a minimal role in protection. *Journal of Immunology*, Vol.171, No. 11, (December 2003), pp. 6039-6045, ISSN 0022-1767
- Karakousis, R. C., Yoshimatsu, T., Lamichhane, G., Wookwine, S. C., Nuermberger, E. L., Grosset, J. & Bishai, W. R. (2004). Dormancy phenotype displayed by extracellular *Mycobacterium tuberculosis* within artificial granulomas in mice. *Journal of Experimental Medicine*, Vol.200, No. 5, (September 2004), pp. 647-657, ISSN 0022-1007
- Kaufmann, S. H. E. (2003). Immunity to intracellular bacteria, In: *Fundamental Immunology*, 5th edition, W. E. Paul (Ed.), pp. 1229-1261, Lippincott Williams & Wilkins Publishers, ISBN 0-7817-3514-9, Philadelphia.
- Kaufmann, S. H. E. (2010a). New vaccines for tuberculosis. *Lancet*, Vol. 375, No. 9731, (June 2010), pp. 2110-2119, ISSN 0140-6736
- Kaufmann, S.H.E. (2010b). Future vaccination strategies against tuberculosis: Thinking outside the box. *Immunity*, Vol.33, No. 4, (October 2010), pp. 567-577, ISSN 1074-7613
- Kaufmann, S.H.E. & Flynn, J.L. (2005). CD8 T cells in tuberculosis. In: *Tuberculosis and the tubercle bacillus*, S. T. Cole, K. D. Eisenach, D. N. McMurray & W. R. Jacobs Jr (Eds.), pp. 465-474, ASM Press, ISBN 1-55581-295-3, Washington, DC.
- Khader, S. A., Bell, G. K., Pearl, J. E., Fountain, J. J., Rangel-Moreno, J., Cilley, G. E., Shen, F., Eaton, S. M., Gaffen, S. L., Swain, S. L., Locksley, R. M., Haynes, L., Randall, T. D. & Cooper, A. M. (2007). IL-23 and IL-17 in the establishment of protective pulmonary CD4⁺ T cell responses after vaccination and during *Mycobacterium tuberculosis* challenge. *Nature Immunology*, Vol.8, No. 4, (April 2007), pp. 369-377, ISSN 1529-2908
- Kursar, M., Koch, M., Mittrücker, H. W., Nouailles, G., Bonhagen, K., Kamradt, T. & Kaufmann, S. H. (2007). Regulatory T cells prevent efficient clearance of *Mycobacterium tuberculosis*. *Journal of Immunology*, Vol. 178, No. 5, (March 2007), pp.2661-2665, ISSN 0022-1767
- Ladel, C. H., Daugelat, S. & Kaufmann, S. H. E. (1995). Immune response to *Mycobacterium bovis* bacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. *European Journal of Immunology*, Vol.25, No. 2, (February 1995), pp. 377-384, ISSN 0014-2980
- Lalvani, A., Brookes, R., Wilkinson, R. J., Malin, A. S., Pathan, A. A., Andersen, P., Dockrell, H., Pasvol, G. & Hill, A. V. (1998). Human cytolytic and interferon γ -secreting CD8⁺ T lymphocytes specific for *Mycobacterium tuberculosis*. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.95, No. 1, (January 1998), pp. 270-275, ISSN 0027-8424

- Larsen, M. H., Biermann, K., Chen, B., Hsu, T., Sambandamurthy, V. K., Lackner, A. A., Aye, P. P., Didier, P., Huang, D., Shao, L., Wei, H., Letvin, N. L., Frothingham, R., Haynes, B. F., Chen, Z. W. & Jacobs Jr., W. R. (2009). Efficacy and safety of live attenuated persistent and rapidly cleared *Mycobacterium tuberculosis* vaccine candidates in non-human primates. *Vaccine*, Vol. 27, No. 34, (July 2009), pp. 4709-4717, ISSN 0264-410X
- Lee, B.-Y. & Horwitz, M. A. (1995). Identification of macrophage and stress-induced proteins of *Mycobacterium tuberculosis*. *Journal of Clinical Investigation*, Vol. 96, No. 1, (July 1995), pp. 245-249, ISSN 0021-9738
- Li, S., Rodrigues, M., Rodriguez, D., Rodriguez, J. R., Esteban, M., Palese, P., Nussenzweig, R. S. & Zavala, F. (1993). Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8⁺ T-cell-mediated protective immunity against malaria. *Proceedings of the National Academy of Science of the United States of America*, Vol. 90, No. 11, (June 1993), pp. 5214-5218, ISSN 0027-8424
- Li, Z., Zhang, H., Fan, X., Zhang, Y., Huang, J., Liu, Q., Tjelle, T. E., Mathiesen, I., Kjekens, R. & Xiong, S. (2006). DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. *Vaccine*, Vol.24, No. 21, (May 2006), pp. 4565-4568, ISSN 0264-410X
- Lowrie, D B., Tascon, R. E., Bonato, V. L. D., Lima, V. M. F., Faccioli, L. H., Stavropoulos, E., Colston, M. J., Hewinson, R. G., Moelling, K. & Silva, C. L. (1999). Therapy of tuberculosis in mice by DNA vaccination. *Nature*, Vol.400, No. 6741, (July 1999), pp. 269-271, ISSN 0028-0836
- Matsumoto, S., Matsumoto, M., Umemori, K., Ozeki, Y., Furugen, M., Tatsuo, T., Hirayama, Y., Yamamoto, S., Yamada, T., Kobayashi, K. (2005). DNA augments antigenicity of mycobacterial DNA-binding protein 1 and confers protection against *Mycobacterium tuberculosis* infection in mice. *Journal of Immunology*, Vol. 175, No. 1, (July 2005), pp. 441-449, ISSN 0022-1767
- Mazzaccaro, R. J., Gedde, M., Jensen, E. R., van Santen, H. M., Ploegh, H. L., Rock, K. L. & Bloom, B. R. (1996). Major histocompatibility complex class I presentation of soluble antigen facilitated by *Mycobacterium tuberculosis* infection. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.93, No. 21, (October 1996), pp. 11786-11791, ISSN 0027-8424
- McShane, H., Brookes, R., Gilbert, S. C. & Hill, A. V. S. (2001). Enhanced immunogenicity of CD4⁺ T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. *Infection and Immunity*, Vol.69, No. 2, (February 2001), pp. 681-686, ISSN 0019-9567
- McShane, H. & Hill, A. (2005). Prime-boost immunisation strategies for tuberculosis. *Microbes and Infection*, vol. 7, No. 5-6, (May 2005), pp. 962-967, ISSN 1286-4579
- McShane, H., Pathan, A. A., Sander, C. R., Keating, S. M., Gilbert, S. C., Huygen, K., Fletcher, H. A. & Hill, A. V. S. (2004). Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. *Nature Medicine*, Vol.10, No. 11, (November 2004), pp. 1240-1244, ISSN 1078-8956
- Miki, K., Nagata, T., Tanaka, T., Kim, Y. H., Uchijima, M., Ohara, N., Nakamura, S, Okada, M. & Koide, Y. (2004). Induction of protective cellular immunity against

- Mycobacterium tuberculosis* by recombinant attenuated self-destructing *Listeria monocytogenes* strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51. *Infection and Immunity*, Vol.72, No. 4, (April 2004), pp. 2014-2021, ISSN 0019-9567
- Mustafa, A. S., Oftung, F., Amoudy, H. A., Madi, N. M., Abal, A. T., Shaban, F., Krands, I. R. & Andersen, P. (2000a). Multiple epitopes from the *Mycobacterium tuberculosis* ESAT-6 antigen are recognized by antigen-specific human T cell lines. *Clinical Infectious Diseases* Vol.30 (Suppl. 3), (June 2000), pp. S201-S205, ISSN 1058-4838
- Mustafa, A. S., Shaban, F. A., Abal, A. T., Al-Attayah, R., Wiker, H. G., Lundin, K. E. A., Oftung, F. & Huygen, K. (2000b). Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted *Mycobacterium tuberculosis* antigen 85B recognized by antigen-specific human CD4⁺ T-cell lines. *Infection and Immunity*, Vol.68, No. 7, (July 2000), pp. 3933-3940, ISSN 0019-9567
- Nagai, S., Wiker, H. G., Harboe, M. & Kinomoto, M. (1991). Isolation and partial characterization of major protein antigens in the culture fluid of *Mycobacterium tuberculosis*. *Infection and Immunity*, Vol.59, No. 1, (January 1991), 372-382, ISSN 0019-9567
- North, R. J. & Jung, Y. J. (2004). Immunity to tuberculosis. *Annual Review of Immunology*, Vol.22, pp. 599-623, ISSN 0732-0582
- Ohara, N., Kitaura, H., Hotokezaka, H., Nishiyama, T., Wada, N., Matsumoto, S., Matsuo, T., Naito, M. & Yamada, T. (1995). Characterization of the gene encoding the MPB51, one of the major secreted protein antigens of *Mycobacterium bovis* BCG, and identification of the secreted protein closely related to the fibronectin binding 85 complex. *Scandinavian Journal of Immunology*, Vol.41, No. 5, (May 1995), pp. 433-442, ISSN 0300-9475
- Olsen, A. W., Williams, A., Okkels, L. M., Hatch, G. & Andersen, P. (2004). Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. *Infection and Immunity*, Vol.72, No. 10, (October 2004), pp. 6148-6150, ISSN 0019-9567
- Orme, I. A. (1988). Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance, in mice inoculated with killed mycobacterial vaccines. *Infection and Immunity*, Vol.56, No. 12, (December 1988), pp. 3310-3312, ISSN 0019-9567
- Ottenhoff, T. H., Kumamaratne, D. & Casanova, J. L. (1998). Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. *Immunology Today*, Vol.19, No. 11, (November 1998), pp. 491-494, ISSN 1471-4906
- Parker, K. C., Bednarek, M. A. & Coligan, J. E. (1994). Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. *Journal of Immunology*, Vol.152, No. 1, (January 1994), pp. 163-175.
- Pethe, K., Alonso, S., Blet, F., Delogu, G., Brennan, M. J., Lochter, C. & Menozzi, F. D. (2001). The heparin-binding haemagglutinin of *M. Tuberculosis* is required for extrapulmonary dissemination. *Nature*, Vol.412, No. 6843, (July 2001), pp. 190-194, ISSN 0028-0836
- Radošević, K., Wieland, C. W., Rodriguez, A., Weverling, G. J., Mintardjo, R., Gillissen, G., Vogels, R., Skeiky, Y. A. W., Hone, D. M., Sadoff, J. C., van der Poll, T., Havenga,

- M. & Goudsmit, J. (2007). Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. *Infection and Immunity*, Vol.75, no. 8, (August 2007), pp. 4105-4115, ISSN 0019-9567
- Ramshow, I. A. & Ramsay, A. J. (2000). The prime-boost strategy: exciting prospects for improved vaccination. *Immunology Today*, Vol.21, No. 4, (April 2000), pp. 163-165, ISSN 0167-5699
- Rammensee, H.-G., Bachmann, J., Emmerich, N. P. N., Bachor, O. A. & Stevanović, S. (1999). SYFPEITHI: database for MHC ligands and peptide. *Immunogenetics*, Vol.50, No. 3-4, (November 1999), pp. 213-219, ISSN 0093-7711
- Reche, P. A., Glutting, J. P., Zhang, H. & Renherz, E. L. (2004). Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. *Immunogenetics*, Vol. 56, No. 6, (September 2004), pp. 405-419, ISSN 0093-7711
- Repique, C. J., Li, A., Collins, F. M. & Morris, S. L. (2002). DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. *Infection and Immunity*, Vol.70, No. 7, (July 2002), pp. 3318-3323, ISSN 0019-9567
- Rodrigues, L. C., Diwan, V. K. & Wheeler, J. G. (1993). Protective effect of BCG against tuberculosis meningitis and miliary tuberculosis: a meta-analysis. *International Journal of Epidemiology*, (December 1993), Vol.22, No. 6, pp. 1154-1158, ISSN 0300-5771
- Romano, M., D'Souza, S., Adnet, P.-Y., Laali, R., Jurion, F., Palfliet, K. & Huygen, K. (2006). Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from *Mycobacterium tuberculosis* increases the survival time of *Mycobacterium bovis* BCG vaccinated mice against low dose intravenous challenge with *M. tuberculosis* H37Rv. *Vaccine*, Vol.24, No. 16, (April 2006), pp. 3353-3364, ISSN 0264-410X
- Roupie, V., Romano, M., Zhang, L., Korf, H., Lin, M Y., Franken, K. L. M. C., Ottenhoff, T. H. M., Klein, M. R. & Huygen, K. (2007). Immunogenicity of eight dormancy regulon-encoded proteins of *Mycobacterium tuberculosis* in DNA-vaccinated and tuberculosis-infected mice. *Infection and Immunity*, Vol.75, No. 2, (February 2007), pp. 941-949, ISSN 0019-9567
- Ruppert, J., Sidney, J., E. Celis, E., Kubo, R. T., Grey, H. M. & Sette, A. (1993). Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. *Cell*, Vol.74, No. 5, (September 1993), pp. 929-937, ISSN 0092-8674
- Sakula, A. (1983). Robert Koch: centenary of the discovery of the tubercle bacillus, 1882. *Canadian Veterinary Journal*, Vol. 24, No. 4, (April 1983), pp. 127-131. ISSN 0008-5286
- Sambandamurthy, V. K., Derrick, S. C., Hsu, T., Chen, B., Larsen, M. H., Jalapathy, K. V., Chen, M., Kim, J., Porcelli, S. A., Chan, J., Morris, S. L. & Jacobs Jr., W. R. (2006). *Mycobacterium tuberculosis* Δ RD1 Δ panCD: A safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. *Vaccine*, Vol.24, No. 37-39, (September 2006), pp. 6309-6320, ISSN 0264-410X
- Scriba, T. J., Tameris, M., Mansoor, N., Smit, E., van der Merwe, L., Isaacs, F., Keyser, A., Moyo, S., Brittain, N., Lawrie, A., Gelderbloem, S., Veldsman, A., Hatherill, M., Hawkrigde, A., Hill, A. V., Hussey, G. D., Mahomed, H., McShane, H. & Hanekom,


- W. A. (2010). Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4⁺ T cells. *European Journal of Immunology*, Vol. 40, No. 1, (January 2010), pp. 279-290, ISSN 0014-2980
- Shen, Y., Zhou, D., Lai, X., Simon, M., Shen, L., Kou, Z., Wang, Q., Jiang, L., Estep, J., Hunt, R., Clagett, M., Sehgal, P. K., Li, Y., Zeng, X., Morita, C. T., Brenner, M. B., Letvin, N. L. & Chen, Z. W. (2002). Adaptive immune response of V γ 2V δ 2⁺ T cells during mycobacterial infections. *Science*, Vol.295, No. 5563, (March 2002), pp. 2255-2258, ISSN 0036-8075
- Singh, H. & Raghava, G.P.S. (2001). ProPred: prediction of HLA-DR binding sites. *Bioinformatics*, Vol.17, No. 12, (December 2001), pp. 1236-1237. ISSN 1367-4803
- Skeiky, Y. A. W., Alderson, M. R., Overndale, P. J., Guderian, J. A., Brandt, L., Dillon, D. C., Campos-Neto, A., Lobet, Y., Dalemans, W., Orme, I. M. & Reed, S. G. (2004). Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. *Journal of Immunology*, Vol.172. No. 12, (June 2004), pp. 7618-7628, ISSN 0022-1767
- Skeiky, Y. A. W., Diethrich, J., Lasco, T. M., Stagliano, K., Dheenadhayalan, V., Goetz, M. A., Cantarero, L., Basaraba, R. J., Bang, P., Kromann, I., McClain, J. B., Sadoff, J. C. & Andersen, P. (2010). Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. *Vaccine*, Vol.28, No. 4, (January 2010), pp. 1084-1093, ISSN 0264-410X
- Skinner, M. A., Ramsay, A. J., Buchan, G. S., Keen, D. L., Ranasinghe, C., Slobbe, L., Collins, D. M., De Lisle, G. W. & Buddle, B. M. (2003). A DNA prime-live vaccine boost strategy in mice can augment IFN- γ responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of *Mycobacterium bovis* against bovine tuberculosis. *Immunology*, vol. 108, No. 4, (April 2003), pp. 548-555, ISSN 0019-2805
- Smith, S. M., Brookes, R., Klein, A. S., Malin, A. S., Lukey, P. T., King, A. S., Ogg, G. S., Hill, A. V. & Dockrell, H. M. (2000). Human CD8⁺ CTL specific for the mycobacterial major secreted antigen 85A. *Journal of Immunology*, Vol. 165, No. 12, (December 2000), pp. 7088-7095, ISSN 0022-1767
- Smith, S.M. & Duckrell, H.M. (2000). Role of CD8⁺ T cells in mycobacterial infections. *Immunology and Cell Biology*, Vol.78, No. 4, (August 2000), pp. 325-333, ISSN 0818-9641
- Stegelmann, F., Bastian, M., Swoboda, K., Bhat, R., Kiessler, V., Krensky, A. M., Roellinghoff, M., Modlin, R. L. & Stenger, S. (2005). Coordinate expression of CC chemokine ligand 5, granulysin, and perforin in CD8⁺ T cells provides a host defense mechanism against *Mycobacterium tuberculosis*. *Journal of Immunology*, Vol. 175, No. 11, (December 2005), pp. 7474-7483, ISSN 0022-1767
- Stenger, S., Mazzaccaro, R. J., Uyemura, K., Cho, S., Barnes, P. F., Rosat, J. P., Sette, A., Brenner, M. B., Porcelli, S. A., Bloom, B. R. & Modlin, R. L. (1997): Differential effects of cytolytic T cell subsets on intracellular infection. *Science*, Vol.276, No. 5319, (June 1997), pp. 1684-1687, ISSN 0036-8075

- Stenger, S.R. & Modlin, L. (1999). T cell mediated immunity to *Mycobacterium tuberculosis*. *Current Opinion in Microbiology*, Vol.2, No. 1, (February 1999), pp. 89-93, ISSN 1369-5274
- Sterne, J.A.C., Rodrigues, L.C. & Guedes, I.N. (1998). Does the efficacy of BCG decline with time since vaccination? *International Journal of Tuberculosis and Lung Disease*, Vol.2, No. 3, pp. 200-207, ISSN 1027-3719
- Stover, C. K., de la Cruz, V. F., Fuerst, T. R., Burlein, J. E., Benson, L. A., Bennett, L. T., Bansal, G. P., Young, J. F., Lee, M. H., Hatfull, G. F., Snapper, S. B., Barletta, R. G., Jacobs Jr., W. R. & Bloom, B. R. (1991). New use of BCG for recombinant vaccines. *Nature*, Vol.351, No. 6326, (June 1991), pp. 456-460, ISSN 0028-0836
- Sugawara, I., Yamada, H., Udagawa, T. & Huygen, K. (2003). Vaccination of guinea pigs with DNA encoding Ag85A by gene gun bombardment. *Tuberculosis (Edinb)*, Vol.83, No. 6, (June 2003), pp. 331-337, ISSN 1472-9792
- Suzuki, D., Nagata, T., Eweda, G., Matsumoto, S., Matsumoto, M., Tsujimura, K. & Koide, Y. (2010). Characterization of murine T-cell epitopes on mycobacterial DNA-binding protein 1 (MDP1) using DNA vaccination. *Vaccine*, Vol.28, No. 8, (February 2010), pp. 2020-2025, ISSN 0264-410X
- Suzuki, M., Aoshi, T., Nagata, T. & Koide, Y. (2004). Identification of murine H2-D^d- and H2-A^b-restricted T-cell epitopes on a novel protective antigen, MPT51, of *Mycobacterium tuberculosis*. *Infection and Immunity*, Vol.72, No. 7, (July 2004), pp. 3829-3837, ISSN 0019-9567
- Tang, S. T., van Meijgaarden, K. E., Caccamo, N., Guggino, G., Klein, M. R., van Weeren, P., Kazi, F., Stryhn, A., Zaigler, A., Sahin, U., Buus, S., Dieli, F., Lund, O. & Ottenhoff, T. H. (2011). Genome-based in silico identification of new *Mycobacterium tuberculosis* antigens activating polyfunctional CD8⁺ T cells in human tuberculosis. *Journal of Immunology*, Vol. 186, No. 2, (January 2011), pp.1068-1080, ISSN 0022-1767
- Tanghe, A., Denis, O., Lambrecht, B., Motte, V., van den Berg, T. & Huygen, K. (2000). Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment. *Infection and Immunity*, Vol.68, No. 7, (July 2000), pp. 3854-3860, ISSN 0019-9567
- Tascon, R. E., Colston, M. J., Ragno, S., Stavropoulos, E., Gregory, D. & Lowrie, D. B. (1996). Vaccination against tuberculosis by DNA injection. *Nature Medicine*, Vol.2, No. 8, (August 1996), pp. 888-892, ISSN 1078-8956
- Tascon, R. E., Stavropoulos, E., Lukacs, K. V. & Colston, M. J. (1998). Protection against *Mycobacterium tuberculosis* infection by CD8⁺ T cells requires the production of gamma interferon. *Infection and Immunity*, Vol.66, No. 2, (February 1998), pp. 830-834, ISSN 0019-9567
- Taylor, J. L., Turner, O. C., Basaraba, R. J., Belisle, J. T., Huygen, K. & Orme, I. M. (2003). Pulmonary necrosis resulting from DNA vaccination against tuberculosis. *Infection and Immunity*, Vol.71, No. 4, (April 2003), pp. 2192-2198, ISSN 0019-9567
- Tchilian, E. Z., Desel, C., Forbes, E. K., Bandermann, S., Sander, C. R., Hill, A. V. S., McShane, H. & Kaufmann, S. H. E. (2009). Immunogenicity and protective efficacy of prime-boost regimens with recombinant *ΔureC hly⁺ Mycobacterium bovis* BCG and modified vaccinia virus Ankara expressing *M. Tuberculosis* antigen 85A against

- murine tuberculosis. *Infection and Immunity*, Vol. 77, No. 2, (February 2009), pp. 622-631, ISSN 0019-9567
- Teitelbaum, R., Gratman-Freedman, A., Chen, B., Robbins, J. B., Unanue, E., Casadevall, A. & Bloom, B. R. (1998). A mAb recognizing a surface antigen of *Mycobacterium tuberculosis* enhances host survival. *Proceedings of the National Academy of Science of the United States of America*, Vol. 95, No. 26, (December 1998), pp. 15688-15693, ISSN 0027-8424
- Tollefsen, S., Tjelle, T. E., Schneider, J. Harboe, M., Wiker, H. G., Hewinson, G., Huygen, K. & Mathiesen, I. (2002). Improved cellular and humoral immune responses against *Mycobacterium tuberculosis* antigens after intramuscular DNA immunisation combined with muscle electroporation. *Vaccine*, Vol.20, No. 27-28, (September 2002), pp. 3370-3378, ISSN 0264-410X
- Turner, J., Rhoades, E. R., Keen, M., Belisle, J. T., Frank, A. A. & Orme, I. M. (2000). Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. *Infection and Immunity*, Vol. 68, No. 3, (March 2000), pp. 1706-1709, ISSN 0019-9567
- van Pinxteren, L. A. H., Cassidy, J. P., Smedegaard, B. H. C., Agger, E. M. & Anersen, P. (2000). Control of latent *Mycobacterium tuberculosis* infection is dependent on CD8 T cells. *European Journal of Immunology*, Vol.30, No. 12, (December 2000), pp. 3689-3698, ISSN 0014-2980
- Walzl, G., Ronacher, K., Hanekom, W., Scriba, T. J. & Zumla, A. (2011). Immunological biomarkers of tuberculosis. *Nature Reviews Immunology*, Vol.11, No. 5, (May 2011), pp. 343-354, ISSN 1474-1733
- Wang, L. X., Nagata, T., Tsujimura, K., Uchijima, M., Seto, S. & Koide, Y. (2009). Identification of HLA-DR4-restricted T-cell epitope on MPT51 protein, a major secreted protein derived from *Mycobacterium tuberculosis* using MPT51 overlapping peptides screening. *Vaccine*, Vol.28, No. 8, (February 2009), pp. 2026-2031, ISSN 0264-410X
- Wiker, H. G. & Harboe, M. (1992). The antigen 85 complex: a major secretion product of *Mycobacterium tuberculosis*. *Microbiological Reviews*, Vol.56, No. 4, (December 1992), pp. 648-661, ISSN 1092-2172
- Winau, F., Weber, S., Sad, S., de Diego, J., Hoops, S. L., Breiden, B., Sandhoff, K., Brinkmann, V., Kaufmann, S. H. E. & Schaible, U. E. (2006). Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. *Immunity*, Vol.24, No. 1, (January 2006), pp. 105-117, ISSN 1074-7613
- World Health Organization. (2010). *WHO Report 2010 Global tuberculosis control*. Available from http://www.who.int/tb/publications/global_report/2010/pdf/full_report.pdf.
- Yoshida, A., Nagata, T., Uchijima, M., Higashi, T. & Koide, Y. (2000). Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses. *Vaccine*, Vol.18, No. 17, (March 2000), pp. 1725-1729, ISSN 0264-410X
- Yoshida, S., Tanaka, T., Kita, Y., Kuwayama, S., Kanamaru, N., Muraki, Y., Hashimoto, S., Inoue, Y., Sakatani, M., Kobayashi, E., Kaneda, Y. & Okada, M. (2006). DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12

confers protection against *Mycobacterium tuberculosis* by T cell activation. *Vaccine*, Vol.24, No. 8, (February 2006), pp. 1191-1204, ISSN 0264-410X

Zhang, X., Divangahi, M., Ngai, P., Santosuosso, M., Millar, J., Zganiacz, A., Wang, J., Bramson, J. & Xing, Z. (2007). Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. *Vaccine*, Vol.25, No. 7, (January 2007), pp. 1342-1352, ISSN 0264-410X



Understanding Tuberculosis - Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity

Edited by Dr. Pere-Joan Cardona

ISBN 978-953-307-942-4

Hard cover, 560 pages

Publisher InTech

Published online 24, February, 2012

Published in print edition February, 2012

Mycobacterium tuberculosis in an attempt to understand the extent to which the bacilli has adapted itself to the host and to its final target. On the other hand, there is a section in which other specialists discuss how to manipulate this immune response to obtain innovative prophylactic and therapeutic approaches to truncate the intimal co-evolution between Mycobacterium tuberculosis and the Homo sapiens.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Toshi Nagata and Yukio Koide (2012). Immune Responses Against Mycobacterium, Understanding Tuberculosis - Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity, Dr. Pere-Joan Cardona (Ed.), ISBN: 978-953-307-942-4, InTech, Available from: <http://www.intechopen.com/books/understanding-tuberculosis-analyzing-the-origin-of-mycobacterium-tuberculosis-pathogenicity/immune-responses-against-mycobacterium-tuberculosis-and-the-vaccine-strategies>

INTECH

open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.